Register
Login:
Share:
Email Facebook Twitter


Tech company Mporium delivers an outstanding set of Q1 results says CEO De Groot
IronRidge Resources CEO hails spectacular lithium project and money making potential for gold


ShareCast News


PureTech partner Gelesis gets FDA approval for weight loss product 'Plenity'

Mon, 15th Apr 2019 09:56


(Sharecast News) - Biopharmaceutical company PureTech Health announced on Monday that its affiliate Gelesis has received marketing clearance from the United States Food and Drug Administration (FDA) for its first product, 'Plenity' (Gelesis100).

The London-listed firm described the product as a "new and differentiated" aid in weight management in adults with a body mass index of between 25-40 kilograms per square metre, when used in conjunction with diet and exercise.

It explained that nearly 150 million adults in the United States fell into that wide BMI range, with Plenity the only prescription weight management product to be cleared for use by overweight adults with a BMI as low as 25, with or without comorbidities such as hypertension, type 2 diabetes or dyslipidemia.

It described Plenity as an orally-administered capsule containing a non-stimulant, non-systemic, superabsorbent hydrogel.

The product was designed to absorb water and increase the volume and elasticity of the stomach and small intestine contents, to help people feel full.

Gelesis planned to initiate a targeted US launch of Plenity in the second half of 2019, and anticipated it would be "broadly available" by prescription in the country in 2020.

"This FDA clearance of Plenity marks a major accomplishment for PureTech Health and Gelesis," said PureTech Health co-founder and chief innovation officer Eric Elenko.

"We congratulate the Gelesis team for bringing a truly novel approach for weight management to a vast population of people who have had limited or no prescription treatment options until now.

"The experienced commercial team at Gelesis is well-positioned to launch this exciting new therapy along with a deep base of investors who will help to support the launch."

Elenko said that, in-line with PureTech's overarching scientific focus and leadership in the BIG axis, Gelesis was developing its novel hydrogel platform technology for other chronic diseases such as non-alcoholic steatohepatitis and inflammatory bowel disease through its proprietary approach, focussed on modulating the gastrointestinal pathway.

"Committed to developing innovative medicines to address some of the largest health issues facing society today, PureTech Health has developed seven novel platforms from concept to clinical validation across our affiliate pipeline.

"FDA clearance of Plenity is a landmark moment, providing strong validation of PureTech's ability to identify and develop an emerging area of biology into a new category of medicine for diseases with significant patient need.

"We look forward to building on this significant milestone with the many upcoming catalysts across our internal and affiliate pipelines."




Back to ShareCast News


Share Price, Share Chat, Stock Market news at lse.co.uk
FREE Member Services
- Setup a personalised Watchlist and Virtual Portfolio.
- Gain access to LIVE real-time Regulatory News (RNS).
- View more Trades, Directors' Deals, and Broker Ratings.
Share Price, Share Chat, Stock Market news at lse.co.uk




Datafeed and UK data supplied by NBTrader and Digital Look. While London South East do their best to maintain the high quality of the information displayed on this site,
we cannot be held responsible for any loss due to incorrect information found here. All information is provided free of charge, 'as-is', and you use it at your own risk.
The contents of all 'Chat' messages should not be construed as advice and represent the opinions of the authors, not those of London South East Limited, or its affiliates.
London South East does not authorise or approve this content, and reserves the right to remove items at its discretion.